Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M).
about
Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and futureA Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes MellitusLixisenatide in type 2 diabetes: latest evidence and clinical usefulnessAdverse Effects of GLP-1 Receptor AgonistsLixisenatide as add-on therapy to basal insulinEffects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetesUpdate on the treatment of type 2 diabetes mellitusPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Switch to Combined GLP1 Receptor Agonist Lixisenatide with Basal Insulin Glargine in Poorly Controlled T2DM Patients with Premixed Insulin Therapy: A Clinical Observation and Pilot Study in Nine Patients.Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes--a study in both people with type 2 diabetes and healthy subjects.GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?The clinical development program of lixisenatide: a once-daily glucagon-like Peptide-1 receptor agonist.Determining predictors of early response to exenatide in patients with type 2 diabetes mellitusEfficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-SInjectable Coformulations in DiabetologyNovel Agents for the Treatment of Type 2 Diabetes.Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-AnalysisLixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects.Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitusThe placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysisEfficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study.Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc AnalysisEffect of the glucagon-like peptide-1 receptor agonist lixisenatide on postprandial hepatic glucose metabolism in the conscious dogA genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease.Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trials.Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus.Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus.Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus.A systematic review and meta-analysis of the efficacy of lixisenatide in the treatment of patients with type 2 diabetes.Pharmacological treatment of diabetes in older people.The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective.GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.Potential side effects to GLP-1 agonists: understanding their safety and tolerability.Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance.Number-Based Approach to Insulin Taxonomy.Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy.Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.Future challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapy
P2860
Q26752699-24D63256-99C3-48D1-B765-8BCB796971D2Q26765155-142CEDFF-4480-44DA-BF4B-F57A9905504CQ26771823-F244C0A4-BECC-4E1A-BAB3-A7FAFD783F7AQ26801346-98CBB695-7C38-4F4C-B953-D358B96A22E5Q27007547-BCF3D976-89C3-4F3E-B335-D7F5BC3D7090Q27025423-0F9B817C-9E81-40EB-906B-A4CE883B131BQ28073342-2F53F4B4-BF92-4505-8F39-1501A1BA4314Q30249371-A6595365-D84E-4FFB-B743-057C080E761EQ33732588-5C4D5740-F079-49A5-B3D0-AE7B6DF56A46Q34543003-D9553965-DED2-41EE-895C-E206EECAF751Q34547492-5CA53464-C91D-487E-A32D-63E04C010A03Q34726309-135450E3-69A7-4955-AD3A-9DDA465AA8FFQ35061423-896CD25C-301B-4D22-9B8B-4D25AB8AE13DQ35192193-70A5482A-D690-4DA0-AB8D-A56F5F0C94C2Q35772586-2F44A6F0-F12C-44A1-AEA5-6503BA188053Q35910421-7E59CD3A-8F1F-4DEE-A645-53EA3CE7752FQ36011993-BBA10B55-195F-48A4-9935-57DDE75270CAQ36554216-23007BEE-A7DA-4ACA-A071-34720377588AQ36972371-260ABE8B-2D43-4492-A91F-F0D709E55C91Q37030680-F08DD21F-5492-438E-8426-DF597A7E61A5Q37193446-37098DD8-0B1F-4956-BC1B-6D90A382D543Q37225065-A381FE4A-C9C2-4C9F-8560-B2FE2B88D984Q37239290-F4DC9261-0D9B-47ED-8EE0-B82B2FA8EA9DQ37439806-1BD09CC5-8A55-4FF6-A268-2C85865928B7Q37568754-9FCEA3EC-A345-4268-A683-01B451D70C43Q37633547-B3D1F078-56D1-43F3-B6DD-BC72FD6C7E9DQ38148574-DC23825A-3ED0-4949-937A-68FDB54FB3B2Q38154623-85609469-F54E-4E2D-8B9B-76C7D97A97E9Q38174283-1F707CB2-50C9-4BDB-A23F-B0665CC7891CQ38183127-0E182524-9467-42B3-ADC2-C4647E38AC02Q38235153-C77006D3-73AC-437F-AED9-1698C637FA4AQ38239573-08F43350-B014-47D0-A4DD-53ED82C7300DQ38243035-FBB61952-77DA-4C6C-9B26-5F5F41903E8DQ38266329-9C2FB824-0212-41A9-9AC9-2769D7FE90F0Q38286444-5D51A90D-D5F9-4538-8F26-5DBC31FE8752Q38542098-9862D6C6-B551-4340-9325-D661CC8E994CQ38583002-B92D30F7-9000-411C-800A-724EE11C7F0BQ38597109-CEA4F8AD-8D99-41E7-8BD2-1C27B635AA0CQ38634679-E4CC9389-89A5-4333-8381-28A2BA902A1FQ38692092-7FBBABA6-DCD8-45FC-BC88-E3E3BDF2FA68
P2860
Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M).
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 March 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy and safety of lixisen ...... lled on metformin (GetGoal-M).
@en
Efficacy and safety of lixisen ...... uately controlled on metformin
@nl
type
label
Efficacy and safety of lixisen ...... lled on metformin (GetGoal-M).
@en
Efficacy and safety of lixisen ...... uately controlled on metformin
@nl
prefLabel
Efficacy and safety of lixisen ...... lled on metformin (GetGoal-M).
@en
Efficacy and safety of lixisen ...... uately controlled on metformin
@nl
P2093
P2860
P356
P1433
P1476
Efficacy and safety of lixisen ...... lled on metformin (GetGoal-M).
@en
P2093
Aniceto Leguizamo Dimas
Patrick Miossec
Ronnie Aronson
Stéphane Saubadu
P2860
P304
P356
10.2337/DC12-2006
P407
P577
2013-03-27T00:00:00Z